From real patient stories to tips on living well, hear firsthand from people who have faced blood cancer.
We’ve also got the latest research and advocacy news, as well as stories from our wonderful fundraisers and donors. You can subscribe to our e-newsletters and event news here.
Patients understand that clinical best practice care begins with an accurate and timely diagnosis.
Jennifer Marx shares insight into being diagnosed with myeloma at almost 27 years old - a condition far more prevalent in older people. Jennifer shares how she navigated the healthcare system, managed treatment and relationships, and her experience having two autologous transplants.
For the third time, selinexor (Xpovio®) will be considered by the Pharmaceutical Benefits Advisory Committee (PBAC) at its November 2022 meeting for the treatment of relapsed/refractory (R/R) myeloma.
During the 22 years Martin Boling has had myeloma, blood cancer of various types has affected four other members of his family too, not just him.
Meet the research team developing a myeloma treatment with maximum efficacy and minimal side effects
Northern Territory local Robert Smith had been living on dialysis for 12 years when he was diagnosed with myeloma. Robert discusses the importance that the support of his wife, Jo was in his journey. He takes us through his story — from diagnosis, to what it was like to travel to Adelaide for life-saving treatment and his recovery.
Andrew was the first person in Western Australia to have the life-changing therapy.
Ann Bruce shares the story of her diagnosis, in her own words.
Ciltacabtagene autoleucel (cilta-cel), is being appraised by the Medical Services Advisory Committee (MSAC) for listing on the Medicare Benefits Schedule.
Dr Piers Blombery explains the basics of molecular testing which informs the treatment of blood cancer.
Associate Professor Michael Dickinson says CAR T-cell therapy is a 'revolutionary step forward'.
To mark Myeloma Awareness Month, Faye Johnsen shares her inspiring approach to living with the incurable blood cancer.
Janice says she "wouldn't be here" had she been diagnosed two years earlier.
Not only is Professor Miles Prince “a true believer in CAR T-cells”, he believes they may even have the potential to cure myeloma one day.
Dr Melissa Cantley hopes that those who have this pre-canerous condition will be able to be tested to understand their risk of developing myeloma.
These two myeloma drugs were not recommended for listing on the PBS.
They’re three women all battling an incurable type of blood cancer, but Neda, Nikki and Shirley have felt hardship in very different ways.
The drug has received a positive recommendation for PBS listing.
Shirley Irwin has had radiotherapy and two transplants, had surgery, five different lines of treatment, and relapsed twice.
Kate Vandyke is leading exciting research examining whether a new inhibitor can be used to prepare myeloma patients for therapies and increase their efficacy.
